153 related articles for article (PubMed ID: 12665524)
1. Binding of urokinase-type plasminogen activator receptor (uPAR) to the mannose 6-phosphate/insulin-like growth factor II receptor: contrasting interactions of full-length and soluble forms of uPAR.
Kreiling JL; Byrd JC; Deisz RJ; Mizukami IF; Todd RF; MacDonald RG
J Biol Chem; 2003 Jun; 278(23):20628-37. PubMed ID: 12665524
[TBL] [Abstract][Full Text] [Related]
2. Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
Schiller HB; Szekeres A; Binder BR; Stockinger H; Leksa V
Mol Biol Cell; 2009 Feb; 20(3):745-56. PubMed ID: 19037107
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms for high affinity mannose 6-phosphate ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor.
Byrd JC; MacDonald RG
J Biol Chem; 2000 Jun; 275(25):18638-46. PubMed ID: 10764735
[TBL] [Abstract][Full Text] [Related]
4. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction.
Nykjaer A; Christensen EI; Vorum H; Hager H; Petersen CM; Røigaard H; Min HY; Vilhardt F; Møller LB; Kornfeld S; Gliemann J
J Cell Biol; 1998 May; 141(3):815-28. PubMed ID: 9566979
[TBL] [Abstract][Full Text] [Related]
5. Opposing roles for the insulin-like growth factor (IGF)-II and mannose 6-phosphate (Man-6-P) binding activities of the IGF-II/Man-6-P receptor in the growth of prostate cancer cells.
Schaffer BS; Lin MF; Byrd JC; Park JH; MacDonald RG
Endocrinology; 2003 Mar; 144(3):955-66. PubMed ID: 12586773
[TBL] [Abstract][Full Text] [Related]
6. An insulin-like growth factor II (IGF-II) affinity-enhancing domain localized within extracytoplasmic repeat 13 of the IGF-II/mannose 6-phosphate receptor.
Devi GR; Byrd JC; Slentz DH; MacDonald RG
Mol Endocrinol; 1998 Nov; 12(11):1661-72. PubMed ID: 9817593
[TBL] [Abstract][Full Text] [Related]
7. Structure of uPAR, plasminogen, and sugar-binding sites of the 300 kDa mannose 6-phosphate receptor.
Olson LJ; Yammani RD; Dahms NM; Kim JJ
EMBO J; 2004 May; 23(10):2019-28. PubMed ID: 15085180
[TBL] [Abstract][Full Text] [Related]
8. IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells.
Chang MH; Kuo WW; Chen RJ; Lu MC; Tsai FJ; Kuo WH; Chen LY; Wu WJ; Huang CY; Chu CH
J Mol Endocrinol; 2008 Aug; 41(2):65-74. PubMed ID: 18495691
[TBL] [Abstract][Full Text] [Related]
9. Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers.
Devi GR; De Souza AT; Byrd JC; Jirtle RL; MacDonald RG
Cancer Res; 1999 Sep; 59(17):4314-9. PubMed ID: 10485478
[TBL] [Abstract][Full Text] [Related]
10. Domain interactions of the mannose 6-phosphate/insulin-like growth factor II receptor.
Kreiling JL; Byrd JC; MacDonald RG
J Biol Chem; 2005 Jun; 280(22):21067-77. PubMed ID: 15799974
[TBL] [Abstract][Full Text] [Related]
11. Soluble M6P/IGF2R released by TACE controls angiogenesis via blocking plasminogen activation.
Leksa V; Loewe R; Binder B; Schiller HB; Eckerstorfer P; Forster F; Soler-Cardona A; Ondrovicová G; Kutejová E; Steinhuber E; Breuss J; Drach J; Petzelbauer P; Binder BR; Stockinger H
Circ Res; 2011 Mar; 108(6):676-85. PubMed ID: 21273553
[TBL] [Abstract][Full Text] [Related]
12. Biotin-Chasing Assay to Evaluate uPAR Stability and Cleavage on the Surface of Cells.
Leksa V; Schiller HB; Stockinger H
Methods Mol Biol; 2018; 1731():39-47. PubMed ID: 29318541
[TBL] [Abstract][Full Text] [Related]
13. The bovine mannose 6-phosphate/insulin-like growth factor II receptor. The role of arginine residues in mannose 6-phosphate binding.
Dahms NM; Rose PA; Molkentin JD; Zhang Y; Brzycki MA
J Biol Chem; 1993 Mar; 268(8):5457-63. PubMed ID: 8449908
[TBL] [Abstract][Full Text] [Related]
14. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.
Høyer-Hansen G; Behrendt N; Ploug M; Danø K; Preissner KT
FEBS Lett; 1997 Dec; 420(1):79-85. PubMed ID: 9450554
[TBL] [Abstract][Full Text] [Related]
15. Dissecting mannose 6-phosphate-insulin-like growth factor 2 receptor complexes that control activation and uptake of plasminogen in cells.
Leksa V; Pfisterer K; Ondrovičová G; Binder B; Lakatošová S; Donner C; Schiller HB; Zwirzitz A; Mrvová K; Pevala V; Kutejová E; Stockinger H
J Biol Chem; 2012 Jun; 287(27):22450-62. PubMed ID: 22613725
[TBL] [Abstract][Full Text] [Related]
16. Type-2 IGF receptor: a multi-ligand binding protein.
Braulke T
Horm Metab Res; 1999; 31(2-3):242-6. PubMed ID: 10226808
[TBL] [Abstract][Full Text] [Related]
17. Dominant-negative effect of truncated mannose 6-phosphate/insulin-like growth factor II receptor species in cancer.
Kreiling JL; Montgomery MA; Wheeler JR; Kopanic JL; Connelly CM; Zavorka ME; Allison JL; Macdonald RG
FEBS J; 2012 Aug; 279(15):2695-713. PubMed ID: 22681933
[TBL] [Abstract][Full Text] [Related]
18. A novel binding site for the human insulin-like growth factor-II (IGF-II)/mannose 6-phosphate receptor on IGF-II.
Delaine C; Alvino CL; McNeil KA; Mulhern TD; Gauguin L; De Meyts P; Jones EY; Brown J; Wallace JC; Forbes BE
J Biol Chem; 2007 Jun; 282(26):18886-94. PubMed ID: 17475626
[TBL] [Abstract][Full Text] [Related]
19. Dimerization of the insulin-like growth factor II/mannose 6-phosphate receptor.
Byrd JC; Park JH; Schaffer BS; Garmroudi F; MacDonald RG
J Biol Chem; 2000 Jun; 275(25):18647-56. PubMed ID: 10764761
[TBL] [Abstract][Full Text] [Related]
20. Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations.
Byrd JC; Devi GR; de Souza AT; Jirtle RL; MacDonald RG
J Biol Chem; 1999 Aug; 274(34):24408-16. PubMed ID: 10446221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
